ACUT on OTC
Accustem Sciences Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development expenses | $281.0K | $138.3K |
| General and administrative expenses | $1.5M | $1.4M |
| Total operating expenses | $1.8M | $1.5M |
| LOSS FROM OPERATIONS | -$1.8M | -$1.5M |
| LOSS, BEFORE INCOME TAX | -$1.8M | -$1.5M |
| NET LOSS | -$1.8M | -$1.5M |
| Net loss per share attributable to common shareholders, basic | -$0.12 | -$0.13 |
| Net loss per share attributable to common shareholders, diluted | -$0.12 | -$0.13 |
| Weighted average common shares outstanding used in computing net loss per share attributable to common shareholders, basic | 15.2M shares | 11.4M shares |
| Weighted average common shares outstanding used in computing net loss per share attributable to common shareholders, diluted | 15.2M shares | 11.4M shares |
Every line of the balance sheet in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $13.9K | $5.0K | |
| Prepaid expenses | $35.5K | $45.4K | |
| Total Current Assets | $49.4K | $50.4K | |
| Equipment, net | $418 | ||
| Other non-current assets | $1.5M | ||
| TOTAL ASSETS | $1.5M | $50.9K | |
| Accounts payable | $703.8K | $804.6K | |
| Related party payable | $4.2M | $2.4M | |
| Accrued expenses | $1.9K | $164.1K | |
| Note Payable | $22.5K | $25.1K | |
| Total Current Liabilities | $5.0M | $3.4M | |
| TOTAL LIABILITIES | $5.0M | $3.4M | |
| Common stock $.001 par value; 150,000,000 shares authorized; 16,072,267 shares issued and outstanding as of December 31, 2025 and 12,100,535 shares issued and outstanding as of December 31, 2024 | $16.1K | $12.1K | |
| Additional paid-in capital | $6.4M | $4.7M | |
| Accumulated deficit | -$9.8M | -$8.0M | |
| TOTAL SHAREHOLDERS EQUITY | -$3.4M | -$3.3M | -$2.1M |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $1.5M | $50.9K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 150.0M shares | 150.0M shares | |
| Common stock shares issued | 16.1M shares | 12.1M shares | |
| Common stock, shares outstanding | 16.1M shares | 12.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$1.8M | -$1.5M |
| Depreciation | $418 | $3.6K |
| Share-based compensation | $88.7K | $69.7K |
| Expenses settled in stock | $79.0K | $233.7K |
| Prepaid expenses | $105.0K | $165.9K |
| Accounts payable | -$100.8K | $226.2K |
| Related party payable | $895.6K | $134.2K |
| Accrued expenses | -$162.2K | $7.6K |
| Net cash used in operating activities | -$850.4K | -$664.1K |
| Advances from related party | $957.0K | $781.1K |
| Payments on note payable | -$97.7K | -$133.4K |
| Net cash provided by financing activities | $859.3K | $647.6K |
| Increase (decrease) in cash | $8.9K | -$16.4K |
| Issuance of Note Payable for payment of prepaid expense | $92.6K | $102.9K |
| Shares issued pending non-cash transaction | $1.5M | |
| Cash paid for interest | $1.9K | $3.4K |
Former names
- AccuStem Sciences LtdMar 12, 2021 to Jul 1, 20212
Recent filings
- Aug 14, 202610-Q
- May 15, 202610-Q
- Apr 14, 202610-K
- Mar 31, 2026NT 10-K
- Nov 26, 20258-K
- Nov 12, 202510-Q
- Aug 14, 202510-Q
- Jun 16, 20254
- Jun 13, 20254
- May 20, 202510-Q
- May 15, 2025NT 10-Q
- Apr 10, 20254
- Apr 8, 20254
- Apr 3, 202510-K
- Mar 31, 2025NT 10-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8